Clinical Scorecard: Association Between Gut-Derived Metabolite Phenylacetylglutamine and the Development of Coronary Heart Disease in Women
At a Glance
Category
Detail
Condition
Coronary Heart Disease (CHD)
Key Mechanisms
Gut microbial metabolism of dietary phenylalanine produces phenylacetylglutamine (PAGln), which interacts with adrenergic receptors influencing cardiovascular risk
Target Population
Women, specifically female registered nurses aged 30-55 years at enrollment
Care Setting
Primary prevention and cardiovascular risk assessment in outpatient or research settings
Key Highlights
Higher plasma PAGln levels are associated with increased risk of incident CHD in women over 11 to 16 years of follow-up.
PAGln levels correlate positively with red/processed meat intake and negatively with vegetable intake.
Adherence to a plant-based diet attenuates the association between high PAGln levels and CHD risk.
Guideline-Based Recommendations
Diagnosis
Consider measuring plasma PAGln levels as a novel biomarker for cardiovascular risk assessment in women.
Management
Encourage adherence to plant-based dietary patterns to potentially reduce PAGln-associated CHD risk.
Limit intake of red and processed meats to lower PAGln levels and associated cardiovascular risk.
Monitoring & Follow-up
Monitor dietary patterns and plasma PAGln levels in women at risk for CHD to guide preventive strategies.
Risks
High PAGln levels may increase risk of coronary heart disease, especially in women with low adherence to plant-based diets.
Patient & Prescribing Data
Women without prior CHD, aged 30-55 at baseline, predominantly nurses in the US
Dietary modification towards plant-based foods may mitigate PAGln-related CHD risk; no pharmacologic interventions detailed.
Clinical Best Practices
Assess dietary intake focusing on animal versus plant food consumption when evaluating cardiovascular risk.
Incorporate lifestyle counseling promoting plant-based diets to reduce gut microbial metabolite-related cardiovascular risk.
Use plasma PAGln measurement as part of research or advanced risk stratification in women at risk for CHD.
by Yoriko Heianza, Saumya Tiwari, Xuan Wang, Jeramie D Watrous, Kathryn M Rexrode, Frank B Hu, Mona Alotaibi, Mohit Jain, Qi Sun, JoAnn E Manson, Lu Qi
